BullFrog AI Announces Licensing Agreement with Johns Hopkins University for Oncology Asset
BullFrog AI Holdings (Nasdaq: BFRG) announced an exclusive license agreement with Johns Hopkins University for prodrug compositions of mebendazole, signed on October 13, 2022. This world-wide, royalty-bearing license allows BullFrog to commercialize N-substituted prodrugs that improve solubility and bioavailability compared to the original compound. The prodrugs target oncology treatments, notably glioblastoma, leveraging BullFrog's AI technology to enhance drug development efficiency. Vin Singh, the CEO, emphasized the potential of this asset in their oncology pipeline. BullFrog AI is committed to advancing precision medicine through machine learning in drug development, aiming to reduce costs and improve patient outcomes.
- Exclusive license agreement with Johns Hopkins University expands oncology development pipeline.
- Rights to commercialize prodrugs of mebendazole with improved solubility and bioavailability.
- Potential to develop therapies for glioblastoma and other oncology indications using AI technology.
- None.
Mebendazole prodrug license further expands the Company’s development pipeline, which includes a Phase 2 ready novel formulation of mebendazole for cancer treatment
GAITHERSBURG, Md., April 18, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced an exclusive license agreement with Johns Hopkins University for prodrug compositions of mebendazole. The exclusive license was signed on October 13, 2022.
The world-wide, royalty-bearing license includes the rights to commercialize N-substituted prodrugs of mebendazole that demonstrate improved solubility and bioavailability relative to the parent compound. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications.
"This asset is another key addition to our oncology development pipeline and provides us with an opportunity to demonstrate how our AI/ML technology can turn promising drug candidates into tangible therapies in a cost-effective and efficient manner," said BullFrog AI’s founder and CEO, Vin Singh, "We are extremely proud of our expanding relationship with Johns Hopkins. We look forward to working with strategic partners to advance the development and monetize this promising asset for the treatment of glioblastoma and possibly additional oncology indications."
About BullFrog AI
BullFrog AI is a digital technology company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
For more information visit BullFrogAI at
Website: www.bullfrogai.com
LinkedIn: https://www.linkedin.com/company/bullfrogai/
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Media Contacts:
Bullfrog AI
Dave Gentry
RedChip Companies, Inc.
BFRG@redchip.com
800-733-2447
SOURCE: BullFrog AI Holdings, Inc.
FAQ
What is the recent development by BullFrog AI Holdings regarding mebendazole?
When was the license agreement for mebendazole signed?
What is the significance of the mebendazole prodrug license for BFRG?
